All questions
Clinical trials: Verzenio (abemaciclib) in HR-positive HER2-negative early breast cancer 9 questions · 4 sources
Questions that apply to every indication of Verzenio are on Verzenio (abemaciclib), all indications .
Clinical trials How was the Verzenio monarchE trial designed? “Graphic illustrating the design of the monarchE phase III global trial of Verzenio for the treatment of adults with node-positive, HR+, HER2– EBC at high risk of recurrence. This study included 2 Cohorts. To be enrolled in Cohort 1 (n=5,120), which is the FDA-approved population, patients had to have 1-3 positive nodes plus tumors that were either ≥5cm or histological Grade 3, or both—or patients with 4+ positive nodes. To be enrolled in Cohort 2 (n=517), patients had to have 1-3 positive nodes and Ki-67 score ≥20%.
Patients in each cohort were randomized 1:1 to receive either Verzenio 150 mg twice daily plus SoC adjuvant ET (Cohort 1, n=2,555; Cohort 2, n=253) or SoC adjuvant ET alone (Cohort 1, n=2,565; Cohort 2, n=264) for 2 years. ET continued for at least 5 years if deemed medically appropriate.” (opens the source at this quote in a new tab) Copy Flag
Who was enrolled in the Verzenio monarchE trial (Cohort 1)? “Of the 5120 patients randomized in cohort 1, the median age was 51 years (range, 22-89 years), 99% were women, 70% were White, 24% were Asian, 1.7% were Black or African American, 2.1% were American Indian or Alaska Native, and 0.1% were Native Hawaiian or Other Pacific Islander; 8% were Hispanic/Latino and 92% were not Hispanic/Latino and 0.2% were not reported/missing. Forty-three percent of patients were premenopausal. Most patients received prior chemotherapy (37% neoadjuvant, 59% adjuvant) and prior radiotherapy (96%). Sixty-five percent of the patients had 4 or more positive lymph nodes with 22% having ≥10 positive lymph nodes, 41% had Grade 3 tumor, and 24% had pathological tumor size ≥50 mm. The majority of patients (99%) had estrogen receptor positive disease and 87% had progesterone receptor positive disease. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).” (opens the source at this quote in a new tab) Copy Flag
Outcome measures What does IDFS mean in the Verzenio monarchE trial? Study results What were the 7-year IDFS results with Verzenio in monarchE? In monarchE, how many were recurrence-free at 4 years with Verzenio vs ET alone? Note: Table 18 columns are Verzenio plus tamoxifen or an aromatase inhibitor (N=2555) and tamoxifen or an aromatase inhibitor alone (N=2565), in that order.
What were Verzenio overall survival results vs endocrine therapy alone in monarchE? What were the 7-year distant relapse-free survival results with Verzenio in monarchE? What did monarchE show about IDFS after Verzenio dose reductions? Note: The dosing page of the Verzenio HCP site cites Goetz et al., NPJ Breast Cancer 2024, for the monarchE dose-reduction analysis.
Long-term data Did Verzenio safety change at the monarchE 5-year analysis? Note: Tables 8 and 9 of the Prescribing Information give the monarchE adverse reaction and laboratory rates.